SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : APPI - Advanced Plant Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?


To: Jim Mills who wrote (1040)11/7/1999 5:20:00 PM
From: Popiye  Read Replies (1) | Respond to of 1263
 
APPI corporate headquarters have moved to NYC during the pink stage. We all look forward to their return to the NASDAQ in the month of November 99.

They have a Corporation Website that explains their products; and on their home page (at the bottom) is a discussion area for customers and investors.

advancedplantpharm.com

Sales Corporate Headquarters:

Advanced Plant Pharmaceuticals Inc.
43 West 33rd St.
Suite 405
New York, N.Y. 10001

Advanced Plant Pharmaceuticals Inc. (APPI) Is Declared Effective by the SEC and is now a Fully Reporting Company.

New York - November 4, 1999 (APPI) Advanced Plant Pharmaceuticals, Inc. a company that utilizes whole plants to develop all natural dietary supplements, is pleased to announce that it has been informed by the Securities and Exchange Commission ("SEC") that the Company is in full compliance with SEC reporting rules and has met all requirements to achieve full reporting status. The Company has thus qualified under the new rules of the NASD (National Association of Securities Dealers) and hopes to resume trading on the OTC Bulletin Board within the next two weeks.

David Lieberman, President and CEO of APPI, stated, "We are quite pleased to join the small percentage of companies that satisfy SEC reporting requirements. The NASD's decision to limit OTCBB listing to those companies which comply with SEC reporting rules enhances the OTCBB as a reliable source of information for investors seeking to invest in smaller companies with strong growth potential". Mr. Lieberman further stated, "We would also like to take this opportunity to thank our faithful shareholders that remained confident in APPI. APPI's competent and skilled management team is in place to lead the Company to achieve the enormous potential that our loyal shareholders recognize".

APPI is also proud to announce that they have moved to a larger headquarters located at 43 West 33rd Street, Suite 405, New York, N.Y., 10001. Tel: (212) 695 3334, Fax: (212) 695 2882. Mr. Barry Clare, Chief Operating Officer for APPI stated, "The larger corporate offices will enable the Company to grow internally as we anticipate increased revenues for the year 2000.

For more information on APPI, please visit the Company's

Web site at www.advancedplantpharm.com

The company hopes to announce further agreements in the near future.

APPI is a company that develops innovative plant formulations and technology for clinical application. APPI has met FDA nutritional specifications for the marketing of its Cholesterol lowering agent "Lo-Chol" in the USA, and has received the first IND from the FDA for a whole plant pharmaceutical, Abavca/ACA, which has the potential as an immunomodulater in the treatment of patients infected with HIV, the virus that causes AIDS. APPI's Whole Plant Pharmaceutical Grade Process is trade secret. Utilization of the APPI process converts a whole plant into a standardized product.

APPI is in the on-going process of establishing exclusive distributorships for the products in the United States and abroad.

This press release contains forward-looking statements. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements

Contact:

Advanced Plant Pharmaceuticals, Inc.

Barry Clare
Tel: (212) 695-3334
Fax:(212) 695-2882

Email: IR@advancedplantpharm.com



To: Jim Mills who wrote (1040)11/8/1999 12:26:00 PM
From: Lee N  Read Replies (1) | Respond to of 1263
 
That's great news, Jim. Hang in there.